Inherited bowel cancer: a review from a surgeon’s perspective
Keywords:Neoplastic and non-neoplastic polyps, PJS, JPS, CS, LS, FAP
Colorectal cancer (CRC) is the second most deadly cancer affecting globally. Although most CRCs seen in young adults are sporadic, hereditary cancer syndromes should be considered as an essential factor. Screening for colorectal cancer aids in the early detection and treatment of early-stage CRC; which reduces mortality rates. This review article aimed to present neoplastic and non-neoplastic polyps and their management from a surgeon's perspective while describing screening protocols in high-risk groups. It also highlighted the etiology, clinical features, diagnosis and management of adenomatous polyps and hereditary bowel cancer syndromes like Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), Cowden syndrome (CS), Lynch syndrome (LS) and familial adenomatous polyposis (FAP). The article summarized the importance of these syndromes as a risk factor in colorectal cancer and identifies these as high-risk group patients in colorectal screening protocols. A summary of the management of these risk factors has been described from a surgeon's point of view.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103.
Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. JNCI. 2017;109(8):322.
Connell LC, Mota JM, Braghiroli MI, Hoff PM. The rising incidence of younger patients with colorectal cancer: questions about screening, biology and treatment. Curr Treat Options Oncol. 2017;18(4):23.
Rosato V, Bosetti C, Levi F, Polesel J, Zucchetto A, Negri E, et al. Risk factors for young-onset colorectal cancer. Cancer Causes Control. 2013;24(2):335-41.
Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Cause Control. 2013;24(6):1207-22.
US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627-37.
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American cancer society, the US multi-society task force on colorectal cancer, and the American college of radiology. CA Cancer J Clin. 2008;58(3):130-60.
Colorectal cancer screening recommendation statement from the Canadian Task Force on Preventive Health Care. JAMC. 2001;165(2):206-8.
Lautrup CK, Mikkelsen EM, Lash TL, Katballe N, Sunde L. Familial colorectal cancer risk may be lower than previously thought: a Danish COHORT study. Cancer Epidemiol. 2015;39(5):714-9.
Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol. 2009;27(5):686-93.
Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325(23):1593-6.
Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large COHORT study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-15.
Bibbins-Domingo K, US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US preventive services task force recommendation statement. Ann Intern Med. 2016;164(12):836-45.
Mărginean CO, Mărginean MO, Simu I, Horvath A, Meliţ LE. Giant tubular adenoma with malignancy clinical characteristics in a female teenager: case report and a review of the literature. Medicine. 2016;95(40):4805.
Myers DJ, Arora K. Villous Adenoma. StatPearls Publishing; 2020.
Bujanda L, Cosme A, Gil I, Arenas-Mirave JI. Malignant colorectal polyps. World J Gastroenterol. 2010;16(25):3103.
Fenoglio CM, Kaye GI, Pascal RR, Lane N. Defining the precursor tissue of ordinary large bowel carcinoma: implications for cancer prevention. Pathol Annual. 1977;12(1):87-116.
Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315-30.
Soetikno RM, Kaltenbach T, Rouse RV, Park W, Maheshwari A, Sato T, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA. 2008;299(9):1027-35.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N E J Med. 1988;319(9):525-32.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genet. 2006;38(7):787-93.
Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol. 2003;162(3):815-22.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genet. 1998;18(1):38-43.
Kopacova M, Tacheci I, Rejchrt S, Bures J. Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol. 2009;15(43):5397-408.
Westerman AM, Entius MM, Baar E, Boor PP, Koole R, Velthuysen ML, et al. Peutz-Jeghers syndrome: 78-year follow-up of the original family. Lancet (London, England). 1999;353(9160):1211-5.
Yano T, Yamamoto H. Vascular, polypoid, and other lesions of the small bowel. Best practice & research. Clin Gastroenterol. 2009;23(1):61-74.
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-63.
Stoffel EM, Boland CR. Genetics and Genetic Testing In Hereditary Colorectal Cancer. Gastroenterology. 2015;149(5):1191-203.
Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet (London, England). 2004;363(9412):852-9.
Rosty C. The role of the surgical pathologist in the diagnosis of gastrointestinal polyposis syndromes. Adv Anatom Pathol. 2018;25(1):1-13.
Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125-30.
Lachlan KL, Lucassen AM, Bunyan D, Temple I. K. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007;44(9):579-85.
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN Guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Ntnl Comprehen Cancer Network. 2017;15(1):9-20.
Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nature reviews. Cancer. 2015;15(3):181-94.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783-8.
Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Am Soc Prevent Oncol. 2017;26(3):404-12.
Barnetson RA, Tenesa A, Farrington SM, Nicholl I, Cetnarskyj R, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N E J Med. 2006;354(26):2751-63.
Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nature reviews. Clin Oncol. 2010;7(3):153-62.
Idos G, Valle L. Lynch Syndrome. In: Adam MP, eds. University of Washington, Seattle: GeneReviews; 2004.
South CD, Hampel H, Comeras I, Westman JA, Frankel WL, Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natnl Cancer Institut. 2008;100(4):277-81.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014;147(2):502-26.
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials. JAMA Oncol. 2018;4(3):379-83.
Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22.
Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Human Mutation. 1994;3(2):121-5.
Björk J, Akerbrant H, Iselius L, Alm T, Hultcrantz R. Epidemiology of familial adenomatous polyposis in Sweden: changes over time and differences in phenotype between males and females. Scand J Gastroenterol. 1999;34(12):1230-5.
Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. N E J Med. 1995;332(13):839-47.
Ellis CN. Colonic adenomatous polyposis syndromes: clinical management. Clin Colon Rect Surg. 2008;21(4):256-62.
Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57(5):704-13.
Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):198-213.
Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum. 1995;38(8):813-30.